Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.

VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.

Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectations. Krystal Biotech has returned roughly 5x over the past 5 years, which puts extra focus on whether the current share price still offers an appealing entry point or mainly reflects past success. Ongoing adoption of its genetic medicine platform can support the current valuation, while concerns...

Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Moby summary of Krystal Biotech, Inc.'s Q2 2026 earnings call

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Krystal Biotech Inc (KRYS) reports strong Q2 2026 results with $119.2 million in global revenue, exceeding patient penetration goals and advancing its pipeline toward multiple registrational studies.

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports.

Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overs

Krystal Biotech, Inc. (NASDAQ:KRYS) reported second-quarter 2026 results on Monday that exceeded earnings expectations but fell short of Wall Street’s revenue estimates, sending the stock down 7.

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +5.29% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Use the IBD Stock Checklist to separate the wheat from the chaff in the stock market, specifically in the red-hot biotech sector.

Krystal Biotech (KRYS) stock drew attention after the company disclosed new information related to KB801, its investigational gene therapy for neurotrophic keratitis, in a patent filing response with the U.S. Patent and Trademark Office. See our latest analysis for Krystal Biotech. Against this backdrop, Krystal Biotech’s share price has moved to US$363.28, with the stock up 7.86% over the past week and showing a 90 day share price return of 38.52%. The 1 year total shareholder return is...

Earlier this month, Krystal Biotech, Inc. was moved from the S&P 600 to the S&P 400, joining the S&P 400 Health Care and Biotechnology indices, and also filed a response with the U.S. Patent and Trademark Office that included single-patient data from its investigational KB801 gene therapy for neurotrophic keratitis. The company emphasized that the observed complete closure of a persistent corneal epithelial defect in one KB801-treated patient came from a discontinued study, carries no safety...

Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

They are riding strong tailwinds that could lift them higher.